One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention
To the Editor The STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent 2) study reported noninferiority and superiority of 1 month vs 12 months of dual antiplatelet therapy (DAPT) on cardiovascular and bleeding events in patients receiving everolimus-eluting stents.
Source: JAMA - Category: General Medicine Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Chromium | Cobalt | Coronary Angioplasty | General Medicine | Heart | Percutaneous Coronary Intervention | Study